Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
A speculative AI gold rush promised creators passive income and digital immortality, but exposed how little control adult workers have over their likenesses, their earnings, and their futures.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results